Brief: BB Biotech: US Drug Pricing Legislation Drives Biotech Business To Adapt For Further Innovation

Bb Biotech

21/10/2022 06:03

Oct 21 (Reuters) - BB BIOTECH AG  BION.S :
    * US DRUG PRICING LEGISLATION DRIVES BIOTECH BUSINESS TO
ADAPT FOR
FURTHER INNOVATION
    * REPORTED NET PROFIT FOR Q3 OF 2022 AMOUNTED TO CHF 210 MN
COMPARED TO A NET LOSS OF CHF 208 MN IN PRIOR-YEAR PERIOD.
    * Q3 NET GAIN WAS CHF 210 MN COMPARED TO A NET LOSS OF CHF
208 MN
FOR SAME PERIOD IN 2021.
    * YEAR-TO-DATE, NET LOSS WAS CHF 323 MN COMPARED TO A NET
GAIN OF
CHF 141 MN AT SAME TIME IN 2021
    * USD/CHF EXCHANGE-RATE FLUCTUATIONS CONTRIBUTED 6.8% TO
PERFORMANCE FOR FIRST NINE MONTHS AND 13.4% FOR USD/EUR
    * INVESTMENT MANAGEMENT TEAM WILL CONTINUE TO LOOK OUT FOR
INVESTMENT OPPORTUNITIES INTO NOVEL, FAIRLY VALUED COMPANIES,
SUCH AS OUR RECENT ADDITIONS CELLDEX AND RIVUS PHARMACEUTICALS

Source text for Eikon:  ID:nEQbpNnPja 
Further company coverage:  BION.S 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))